{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:26:02Z","timestamp":1787199962308,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Acute myeloid leukemia (AML) with concurrent multiple fusion genes is extremely rare and characterized by high malignancy, poor chemotherapy response, and dismal prognosis. Here we report a 32-year-old male patient diagnosed with\n                    <jats:italic>de novo<\/jats:italic>\n                    high-risk AML harboring BCOR mutations, AML1-MDS1\/EVI1, AML1-EAP, and BCR-ABL1 p210 fusion genes. The patient received induction chemotherapy with IA+VEN (idarubicin, cytarabine and venetoclax) regimen and achieved complete remission (CR); however, disease progression occurred during the first consolidation therapy. Subsequently, salvage chemotherapy combined with dasatinib was administered, and the patient reattained complete remission with incomplete hematologic recovery (CRi). The patient then underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from his HLA-mismatched father. Post-transplant maintenance therapy consisting of chidamide, decitabine, and dasatinib was administered regularly. At the latest follow-up 3 months after transplantation, the patient remained in continuous molecular remission, with negative minimal residual disease (MRD) and significantly reduced BCR::ABL1 and EVI1 transcript levels. This case indicates that individualized sequential therapy including targeted agents, combination chemotherapy, allo-HSCT with chidamide-containing conditioning, and post-transplant epigenetic maintenance may provide effective disease control and favorable long-term outcomes for ultra-high-risk AML with multiple adverse molecular abnormalities.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1917473","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:48Z","timestamp":1787199348000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare acute myeloid leukemia harboring BCR\/ABL1 (P210), AML1-MDS1\/EVI1, and AML1\/EAP: case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Du","family":"Lijun","sequence":"first","affiliation":[{"name":"Department of Hematology, Mianyang Central Hospital","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mianyang Central Hospital","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01099-7","article-title":"The global epidemiology of acute myeloid leukaemia","volume":"23","author":"El Chaer","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: An open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1046\/j.1365-2141.1997.2143029.x","article-title":"Establishment of a novel human myeloid leukaemia cell line (HNT-34) with t(3,3)(q21;q26), t(9,22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR\/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome","volume":"98","author":"Hamaguchi","year":"1997","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-323-99622-8.00020-4","article-title":"Study of genes involved in chronic myeloid leukemia with t(3, 21)(q26; q22) in blastic crisis","volume":"27","author":"Liu","year":"2006","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000035721","article-title":"A primary pediatric acute myelomonocytic leukemia with t(3,21)(q26;q22): A case report","volume":"102","author":"Duan","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8917","article-title":"A rare presentation of BCR-ABL1 and RUNX1-MECOM rearrangement in a pediatric patient with acute myeloid leukemia","volume":"12","author":"Alamri","year":"2024","journal-title":"Clin Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.05.005","article-title":"RUNX1-ETO and RUNX1-EVI1 differentially reprogram the chromatin landscape in t(8,21) and t(3,21) AML","volume":"19","author":"Loke","year":"2017","journal-title":"Cell Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03787-z","article-title":"Outcome of 3q26.2\/MECOM rearrangements in chronic myeloid leukemia","volume":"120","author":"Akiyama","year":"2024","journal-title":"Int J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2483094","article-title":"RUNX1::MECOM rearrangement in myeloid neoplasm post cytotoxic therapy following sarcoma treatment: a case presentation and review of the literature","volume":"30","author":"Sandnes","year":"2025","journal-title":"Hematology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21797","article-title":"t(3,21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy","volume":"106","author":"Yin","year":"2006","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1201\/9781003513469-19","article-title":"Clinical analysis of myeloid neoplasms with t(3,21) (q26;q22)","volume":"40","author":"Li","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.2870110405","article-title":"AML1 fusion transcripts in t(3,21) positive leukemia: evidence of molecular heterogeneity and usage of splicing sites frequently involved in the generation of normal AML1 transcripts","volume":"11","author":"Sacchi","year":"1994","journal-title":"Genes Chromosomes Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-85232-9_24","article-title":"Rearrangement of the AML1\/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties","volume":"211","author":"Zent","year":"1996","journal-title":"Curr Top Microbiol Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.3.1044","article-title":"The chimeric genes AML1\/MDS1 and AML1\/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1\/MDS1 has tumor-promoter properties","volume":"93","author":"Zent","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0646","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities","volume":"28","author":"Gr\u00f6schel","year":"2010","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03774-z","article-title":"Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis","volume":"98","author":"Wu","year":"2019","journal-title":"Ann Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01048-1","article-title":"The role of EVI1 gene quantification in AML patients with 11q23\/MLL rearrangement after allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Jiang","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2721-z","article-title":"BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features","volume":"95","author":"Neuendorff","year":"2016","journal-title":"Ann Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24928","article-title":"Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT)","volume":"93","author":"Lazarevic","year":"2018","journal-title":"Am J Hematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-024-01069-9","article-title":"Imatinib with intensive chemotherapy in AML with t (9,22)(q34.1;q11.2)\/BCR::ABL1. A DATAML registry study","volume":"14","author":"Gondran","year":"2024","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205095","article-title":"Cooperation of BCR-ABL and AML1\/MDS1\/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia","volume":"20","author":"Cuenco","year":"2001","journal-title":"Oncogene"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092095","article-title":"Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia","volume":"13","author":"Eckardt","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0677-z","article-title":"Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia","volume":"55","author":"Ma","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1182\/blood-2023-174879","article-title":"Safety and efficacy of azacitidine and chidamide maintenance after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia: interim analysis of a prospective, multicenter, single-arm, phase II clinical trial","volume":"142","author":"Yang","year":"2023","journal-title":"65th ASH Annu Meeting Abstracts"},{"key":"B33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13148-025-01987-w","article-title":"Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT","volume":"17","author":"Wu","year":"2025","journal-title":"Clin Epigenet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1917473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:49Z","timestamp":1787199349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1917473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1917473"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1917473","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1917473"}}